We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+36.87%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$311M
AUM Growth
+$137M
Cap. Flow
+$83.9M
Cap. Flow %
26.99%
Top 10 Hldgs %
74.66%
Holding
36
New
8
Increased
5
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$68.4M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10.4M
3
SYRE icon
Spyre Therapeutics
SYRE
+$7.37M
4
GERN icon
Geron
GERN
+$5.82M
5
STRO icon
Sutro Biopharma
STRO
+$5.28M

Top Sells

Rank Stock Value
1
LQDA icon
Liquidia Corp
LQDA
+$4.78M
2
TPST icon
Tempest Therapeutics
TPST
+$3.97M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$3.59M
4
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$2.46M
5
SWTX
SpringWorks Therapeutics
SWTX
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 97.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMTX
1
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$73.4M 23.61%
+1,578,388
New +$68.4M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$23.4M 7.53%
557,356
-67,925
-11% -$2.42M
ODT
3
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$21M 6.76%
496,505
-26,132
-5% -$846K
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$20.5M 6.6%
342,946
-58,100
-14% -$3.59M
ICPT
5
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$19.3M 6.22%
403,688
– –
ALLK
6
DELISTED
Allakos
ALLK
$17.5M 5.64%
243,868
-27,097
-10% -$1.82M
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.2M 5.53%
3,370,478
+2,507,926
+291% +$10.4M
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$15.9M 5.1%
157,190
-15,470
-9% -$1.39M
STRO icon
9
Sutro Biopharma
STRO
$379M
$13M 4.18%
167,558
+55,000
+49% +$5.28M
BCEL
10
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$10.9M 3.49%
510,296
-86,542
-15% -$1.53M
SYRE icon
11
Spyre Therapeutics
SYRE
$8.87B
$8.95M 2.88%
+38,700
New +$7.37M
GERN icon
12
Geron
GERN
$911M
$8.48M 2.73%
+3,890,220
New +$5.82M
ARAV
13
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.71M 2.16%
576,066
– –
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$7B
$6.16M 1.98%
276,289
– –
FULC icon
15
Fulcrum Therapeutics
FULC
$248M
$5.38M 1.73%
+294,118
New +$4.63M
PTLA
16
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$5.28M 1.7%
318,429
+158,657
+99% +$2.21M
PVLA
17
Palvella Therapeutics
PVLA
$1.98B
$5.2M 1.67%
20,253
– –
HOOK
18
DELISTED
HOOKIPA Pharma
HOOK
$4.65M 1.5%
40,025
-13,000
-25% -$1.27M
ACRS icon
19
Aclaris Therapeutics
ACRS
$730M
$4.22M 1.36%
2,608,117
– –
AIMT
20
DELISTED
Aimmune Therapeutics
AIMT
$3.89M 1.25%
232,571
– –
KALA icon
21
KALA BIO
KALA
$11.8M
$3.56M 1.15%
136
+110
+423% +$3.12M
BLU
22
DELISTED
BELLUS Health Inc.
BLU
$3.45M 1.11%
333,631
-60,800
-15% -$616K
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$348M
$2.89M 0.93%
138,197
+10,000
+8% +$180K
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$2.04M 0.65%
168,174
– –
ATXS
25
DELISTED
Astria Therapeutics
ATXS
$1.93M 0.62%
50,000
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q2 2020 Portfolio in Review

As of Q2 2020, Samsara BioCapital held 36 positions worth $311M, up 79% from $174M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Samsara BioCapital deployed $83.9M of net new capital in Q2 2020, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,578,388 shares worth $73.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Principia Biopharma Inc. Common Stock, an estimated $3.59M trimmed.

  • Samsara BioCapital's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,578,388 shares worth $73.4M.
  • Samsara BioCapital added most to IVERIC bio, Inc. Common Stock in Q2 2020, an estimated $10.4M increase.
  • Samsara BioCapital's biggest Q2 2020 reduction was Principia Biopharma Inc. Common Stock, cutting an estimated $3.59M.
  • Samsara BioCapital fully exited Liquidia Corp in Q2 2020, selling an estimated $4.78M.
  • Samsara BioCapital's ten largest holdings make up 75% of its $311M portfolio in Q2 2020.
  • Samsara BioCapital opened 8 new positions and closed 4 in Q2 2020.
  • Samsara BioCapital's portfolio value rose 79% quarter-over-quarter to $311M.

Based on Samsara BioCapital's 13F filing for Q2 2020, filed 14 Aug 2020.